Ethyreal Bio

Ethyreal Bio, Inc.Ethyreal Bio, Inc. specializes in creating therapies for thyroid-related disorders. Founded in Cambridge, US, the company has undergone strategic developments to enhance its operational focus. Ethyreal Bio is primarily focused on the development of innovative therapies for Thyroid Eye Disease (TED) and Graves’ Disease, with its flagship product being ETHY-001. This investigational therapy is designed to precisely target the causal disease processes underlying these conditions by blocking autoantibody activation of the TSH receptor (TSHR). ETHY-001 aims to offer a differentiated therapeutic approach for patients suffering from TED and Graves’ Disease, providing a potentially best-in-class anti-TSHR antibody.Ethyreal Bio's revenue model is structured around the development and potential commercialization of its investigational therapies, including ETHY-001. Transactions within the business typically occur through partnerships with healthcare providers and institutions, where agreements may involve clinical trial collaborations and future product distribution contracts. As the company progresses through clinical trials and moves towards regulatory approval, it may establish pricing plans based on established market rates for similar biologic therapies. The anticipated revenue streams will arise from both direct sales to healthcare institutions and possible licensing agreements with pharmaceutical partners. These collaborative relationships are crucial for bringing their products to market and generating ongoing revenue. The company is also targeting expansion into European and Asian markets, enhancing its reach and impact in treating these disorders. Specific timelines for product launches and regional expansions have not been detailed.

1. Series B

   Jun 10, 2026

   Amount

   $60M

   Investors

   Locked

2. Series A

   Date not disclosed

   Amount

   Undisclosed

   Investors

   Locked